Grit Biotechnology Showcases Cutting-Edge Advances at ASGCT 2025 Annual Meeting

Grit Biotechnology Showcases Cutting-Edge Advances at ASGCT 2025 Annual Meeting



Grit Biotechnology Co., Ltd. (commonly referred to as Grit Bio) has made headlines with its latest announcements ahead of the 28th annual meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place from May 13th to 17th in New Orleans, LA. This clinical-stage biotech firm is known for pioneering novel immunotherapy technologies and is set to present three significant research programs in collaboration with Vitalgen BioPharma Co., Ltd.

The three projects will be highlighted in an oral presentation and two poster sessions at the conference. Each aims to advance the landscape of cancer treatment through innovative approaches to immunotherapy.

Research Highlights



1. APC-Targeted LNP Enables Systemic Delivery of Neoantigen mRNA Vaccines and Enhanced Antigen-Specific T Cell Responses
- Presentation Type: Oral
- Time: Thursday, May 15th, 5:15 - 5:30 PM local time
- Speaker: Pin Wang, Ph.D., Chief Scientific Officer of Grit Biotechnology

2. In Vivo CAR-T Therapy Powered by Novel CLAMP Technology for T cell-Targeted mRNA Delivery
- Presentation Type: Poster
- Time: Wednesday, May 14th, 5:30 - 7:00 PM local time
- Poster #: 1282

3. Enhancing Production and Functional Potential of Tumor-Infiltrating Lymphocytes via Lipid Nanoparticle-Mediated CRISPR/Cas9 Gene Editing
- Presentation Type: Poster
- Time: Thursday, May 15th, 5:30 - 7:00 PM local time
- Poster #: 1776

The innovative APC-targeted lipid nanoparticles (LNP) technology aims not only to improve the delivery of mRNA vaccines targeting neoantigens but also to generate robust antigen-specific T cell responses. This could mark a significant breakthrough in cancer vaccination strategies that harness the body's immune system.

The second presentation focuses on the integration of novel CLAMP technology in CAR-T therapies, which offers exciting prospects for mRNA delivery specifically to T cells. As CAR-T therapy continues to gain ground in the fight against cancer, such targeted innovations could enhance treatment efficacy.

The final poster will showcase advancements in increasing the production and efficacy of tumor-infiltrating lymphocytes (TIL) using CRISPR/Cas9 systems facilitated by lipid nanoparticles. This technique has the potential to revolutionize how TILs are expanded and utilized in therapeutic settings.

Leadership Comments



Dr. Yarong Liu, the founder and CEO of Grit Biotechnology, shared insights on the collaborative efforts saying, "Through a strategic collaboration with Vitalgen, we are pioneering next-generation immunotherapies and precision delivery technologies. This synergy accelerates the development of advanced therapies with transformative improvements in safety and efficacy. We are now expanding those innovations toward global clinical implementation."

Grit Bio’s dedication to advancing immunotherapy is further underscored by their commitment to enhancing safety and effectiveness through innovative research collaborations.

About Grit Biotechnology



Founded in 2019, Grit Biotechnology has quickly established itself as a leading voice in the realm of biopharmaceuticals, focusing specifically on immune cell treatments for cancer. The company has an extensive R&D pipeline, particularly concentrated on TIL therapies. Their proprietary injectable, GT101, is the first TIL therapy now advancing through registrational clinical trials. It is currently in pivotal Phase II studies. Additionally, GT201, the first TIL therapy featuring membrane-bound IL-15 complex, has secured Investigational New Drug (IND) approval in both the United States and China.

With core platforms like StemTexp® for TIL expansion, StaViral® for stably virus-transfected cell lines, and others, Grit strives to develop revolutionary treatments for solid tumors, delivering hope to patients.

For more details about their research and ongoing projects, check out their official website at www.grit-bio.com.

About Vitalgen BioPharma



Vitalgen BioPharma, founded in 2020, is another key player in this collaboration. This biotech company is focused on developing transformative gene therapies and operates state-of-the-art facilities compliant with both China GMP and US cGMP standards. With an emphasis on innovation and patient-centered solutions, Vitalgen creates opportunities for various therapeutic applications using their proprietary platforms.

For additional information visit www.vitalgen.com.

Looking Ahead



As Grit Biotechnology prepares for its presentations at ASGCT 2025, the implications of their work could redefine therapeutic approaches to cancer treatment globally. The ongoing advancements in immunotherapy represent not only hope for patients affected by cancer but also a significant shift toward personalized medicine in oncology.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.